Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is an American biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for serious medical conditions. The company focuses its proprietary technology platforms on proprietary antibody discovery across therapeutic areas including ophthalmology, immunology, oncology, hematology, and rare diseases. Its commercial drug portfolio includes flagship therapeutics such as Eylea for age-related macular degeneration, Dupixent (developed with Sanofi) for eczema and asthma, Libtayo for cancer, and Praluent for hypercholesterolemia. Principal revenue drivers consist of net product sales of proprietary medicines, profit-sharing collaborations with Sanofi and Bayer, and royalty income from international distribution agreements. Regeneron serves broad global end markets encompassing ophthalmologists, allergists, oncologists, hospital systems, specialty pharmacies, and patients across the United States, Europe, and Asia-Pacific. The corporation occupies a leading market position in biotechnology as a pioneer in human genetics-guided drug discovery and targeted biopharmaceutical therapies. Headquartered in Tarrytown, New York, the company's common stock is listed on the Nasdaq Stock Market under the ticker symbol REGN and is a component of the S&P 500 index.
105 of the funds FundTelligence covers report a position in Regeneron Pharmaceuticals.
- Legal name
- Regeneron Pharmaceuticals Inc.
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 105
Funds holding Regeneron Pharmaceuticals
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 5.88 % (full portfolio disclosed, October 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 3.83 % (full portfolio disclosed, September 2026)
- Fondsfinans Global Helse — Fondsfinans · 3.5 % (full portfolio disclosed, October 2026)
- DWS Invest CROCI Sectors Plus — DWS · 3.3 % (full portfolio disclosed, June 2026)
- DNB Health Care — DNB · 2.7 % (full portfolio disclosed, September 2026)
- DWS Invest CROCI US — DWS · 2.26 % (full portfolio disclosed, June 2026)
- DNB Bioteknologi — DNB · 1.46 % (full portfolio disclosed, September 2026)
- JPM Global Healthcare Fund — JPM · 1.33 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 105 funds holding it.